跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
郭 德輝
Doctor
內科部
電子郵件
tk2026
gmail
com
h-index
336
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2025
每年研究成果
概覽
指紋
網路
研究成果
(26)
類似的個人檔案
(7)
指紋
查看啟用 Te-Hui Kuo 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Hemodialysis
100%
End Stage Renal Disease
75%
Cohort Study
61%
Chronic Kidney Failure
51%
Cardiovascular Disease
45%
Insulin Dependent Diabetes Mellitus
39%
All Cause Mortality
32%
Non Insulin Dependent Diabetes Mellitus
22%
Bloodstream Infection
21%
Case-Control Study
21%
Arteriovenous Fistula
19%
Cross-Sectional Study
19%
Rosuvastatin
19%
Drug Induced Disease
19%
Sclerostin
19%
Microorganism
19%
Evocalcet
19%
Cinacalcet
19%
Urinary Tract Infection
19%
Diabetic Retinopathy
19%
Systemic Lupus Erythematosus
19%
Retinopathy
19%
Matrix-Assisted Laser Desorption/Ionization
19%
Diabetes Mellitus
19%
Vitamin D
19%
Peritonitis
19%
Escherichia coli
19%
Overall Survival
19%
Disease Exacerbation
19%
Acarbose
19%
Randomized Clinical Trial
19%
Biological Marker
19%
Infectious Agent
16%
Major Adverse Cardiac Event
8%
Prevalence
7%
Disease Course
6%
Plasminogen Activator Inhibitor 1
6%
Gelatinase A
6%
Adverse Outcome
6%
Comorbidity
6%
Stenosis
5%
Placebo
5%
Postoperative Complication
5%
Immaturity
5%
Medicine and Dentistry
Chronic Kidney Disease
60%
End Stage Renal Disease
53%
Kidney Function
35%
Cardiovascular System
32%
Hemodialysis
24%
Patient with Type 1 Diabetes
23%
Glomerular Filtration Rate
22%
Cardiovascular Disease
21%
Vascular Access
21%
Case-Control Study
21%
Urinary Tract Infection
19%
Arterial Stiffness
19%
Cohort Analysis
19%
Insulin Dependent Diabetes Mellitus
19%
Health Care Cost
19%
Blood Pressure Monitoring
19%
Retinopathy
19%
Diabetic Retinopathy
19%
Systemic Lupus Erythematosus
19%
All Cause Mortality
19%
Disease Exacerbation
19%
Pulse Rate
19%
Waldenström's Macroglobulinemia
19%
Glomerulonephritis
19%
Hepatitis B
19%
Sodium Dihydrogen Phosphate
19%
Phosphate Nephropathy
19%
Severe Dengue
19%
Blood Pressure
19%
Seasonal Variation
19%
Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry
19%
Cryoglobulinemia
19%
Biological Marker
19%
Hepatitis B Virus
16%
Renal Replacement Therapy
11%
Systolic Blood Pressure
11%
Major Adverse Cardiac Event
8%
Proportional Hazards Model
8%
Prevalence
7%
Diseases
7%
Outpatient
7%
Adverse Outcome
6%
Gelatinase A
6%
Plasminogen Activator Inhibitor-1
6%
Hepatitis B Antigen
5%
Immunosuppressive Treatment
5%
Keyphrases
Southern Taiwan
19%
Clinical Characteristics
19%
Clinical Database
19%
Calcimimetics
19%
Evocalcet
19%
Cinacalcet
19%
Cryoglobulinemic Glomerulonephritis
19%
Vascular Access for Hemodialysis
19%
Fistula Patency
19%
Acute Phosphate Nephropathy
19%
Clinical Setting
19%
Oral Sodium Phosphate
19%
Escherichia Coli
19%
Multi-state Modeling
19%
Hepatic Safety
19%
BACTEC FX
19%
Microbiological Characteristics
19%
Peritoneal Dialysis-related Peritonitis
19%
Peritoneal Transport
19%
Peritoneal Equilibration Test
19%
Peritonitis
9%
Vascular Access Creation
8%
Trajectory Change
8%
Monomicrobial
7%
Blood Culture System
7%
Microorganism Concentration
7%
Disease Development
6%
Vitamin D Treatment
6%
High-dose Vitamin D
6%
Polymicrobial
5%
Treatment Failure
5%
Peritoneal Dialysis
5%
Spine Bone
5%
High Phosphate
5%
Severe Secondary Hyperparathyroidism
5%
Bowel Cleansing
5%
High Transporters
5%
